Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic HIV dendritic cell vaccination with or without TLR-3 agonist after ART interruption
2015-000511-40Phase 2Active
- Sponsor
- Inserm-ANRS
- Start
- Oct 2019
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of poly iclc in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Inserm-ANRS. Primary endpoint: Virological efficacy endpoint. Started Oct 2019; status: active.
02
Drugs
poly iclc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2015-000511-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000511-40.